A new approach to evaluate Clinical Heterogeneity in Cystic Fibrosis

Damian Shackleton


We present here an extension of Cystic fibrosis, which is a lethal genetic disease, based on the previous work over the past decade regarding the genetically conferred variation. Our study has examined half a million polymorphic sites within identified regions. We identified chromosomal locations that identify specific genes as contributing to this variation. Furthermore, we sampled thousands of genes and their products of transcriptomic and proteomic data, which contribute to the clinical heterogeneity. These innovative approaches are able to profile identifies putative disease-modifying processes. Our research provides a new insight regards to Cystic fibrosis, which may open new therapeutic avenues to exploration.


  • There are currently no refbacks.

Paper submission email: AJHD@KnowledgeAustralia.com

ISSN (Paper)application pending

ISSN (Online)application pending